Stryker has introduced its automated external defibrillator (AED) LIFEPAK CR2 in the US after receiving pre-market approval (PMA) by the US Food and Drug Administration (FDA).
Featuring AED programme manager LIFELINKcentral, LIFEPAK CR2 is designed to perform cardiopulmonary resuscitations (CPR). It is one of the only machines that can conduct CPR during electrocardiogram (ECG) analysis, which is achieved using cprINSIGHT technology.
LIFEPAK CR2 features a child mode that reduces the amount of energy used during defibrillation, as well as a bilingual option that can be used to access a second pre-set language.
It can be linked to LIFELINKcentral using Wi-Fi connectivity, allowing the AED manager to remotely monitor and manage the device.
LIFEPAK CR2 also sends real-time email notifications when the device is in use and the defibrillator pads have been placed on a patient.
Real-time event data such as heart rhythms and shocks delivered can also be sent to incoming emergency services using the LIFENET AED event viewer.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Stryker emergency care public access vice-president and general manager Ryan Landon said: “The LIFEPAK CR2 is designed to help rescuers provide higher quality CPR and to provide the fastest first shock when defibrillation is needed. Everything about it is designed to increase user confidence.
“The LIFEPAK CR2 harnesses the benefits of connectivity to provide a foundation for better care throughout the entire chain of survival and to simplify AED program management for our customers.”
The company already launched the defibrillation solution in Europe and Canada in 2017 and in Japan in 2018.